References

  1. NuvaRing Summary of Product Characteristics.
  2. Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E. Why consider vaginal drug administration? Fertil Steril 2004;82(1):1–12.
  3. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74(6):451–457.
  4. Oddsson K, Leifels-Fischer B, de Melo NR, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005;71(3): 176–182
  5. Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod 2005;20(2):557–562.
  6. Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002;186(3):389–395.
  7. Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21(9):2304–2311.
  8. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001;16(3):469–475.
  9. Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999;180(2 Pt 2):276–279.
  10. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive Contraception 2005;72(3):168–174.
  11. Timmer CJ and Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39(3):233–342.
  12. Novák A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003;67(3):187–194.
  13. Mulders TM, Dieben TO, Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002;17(10):2594–2599.
  14. Organon data on file.
  15. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100(3):585–593.
  16. Gilliam M, Homquist S, Berlin A. Factors associated with willingnes to use the contraceptive vaginal ring. Contraception 2007;76(1):30–34.
  17. Oddens BJ, Arnolds HT, Van Maris MG, Van Lunsen HW. The dynamics of oral contraceptive use in the Netherlands 1990–1993. Adv Contracept 1994;10(3):167–174.
  18. Kaptein M and Zampaglione E. Poster presented at Annual Meeting of the American College of Obstetricians and Gynecologists, San Francisco May 7–11 2005.
  19. Tuppurainen M, Klimscheffskii R, Venhola M, Dieben TO. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study. Contraception 2004;69(5):389–394.
  20. Archer D, Raine T, Philip Darney P, Nancy J Alexander NJ. An open-label noncomparative study to evaluate the vagina and cervix of NuvaRing® users. Fertil Steril 2002;78(Suppl 1):S25.
  21. Massai R, Mäkäräinen L, Kuukankorpi A, et al. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. Hum Reprod 2005;20(10):2764–2768.
  22. Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. Clin Pharmacokinet 2005;44(4):429–438.

 

 

 

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to MSD Drug Safety Department on 01707 363773

Organon

Expiry 10/11 - NUV.10.GB.27040.AV

© 2010 Copyright Organon Laboratories Limited. All rights reserved.

Terms and Conditions
Privacy Policy


© 2010 Organon Laboratories Ltd trading as MSD: Registered Address: Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU.
A company registered in England and Wales. Company Registration Number: 820771